The present study was conducted to assess the relationship between anemia and pulse pressure (PP) and hypertension (HTN). Data from 16,060 adults (aged ≥20 years) in the fifth Korean National Health and Nutrition Examination Survey (2010-2012) were analyzed. Several key findings were identified. First, after adjusting for related variables, the odds ratio (OR) of anemia (hemoglobin <13 and <12 g/dL, in men and women, respectively), using the normal PP group (PP ≤61 mmHg) as a reference, was significant for the high PP cohort (PP >61 mmHg; OR, 1.517; 95% confidence interval [CI], 1.270-1.812). Second, after adjusting for related variables (except body mass index [BMI] and waist measurement [WM]), the OR of anemia, with a normal blood pressure group as a reference, was significant for the HTN group (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or use of HTN medications; OR, 0.835; 95% CI, 0.709-0.983). However, when further adjusted for BMI and WM, anemia was not associated with HTN (OR, 0.884; 95% CI, 0.750-1.042). In conclusion, anemia was positively associated with high PP, but was not associated with HTN.

Download full-text PDF

Source
http://dx.doi.org/10.1080/10641963.2017.1416123DOI Listing

Publication Analysis

Top Keywords

relationship anemia
8
anemia pulse
8
pulse pressure
8
pressure hypertension
8
national health
8
health nutrition
8
nutrition examination
8
examination survey
8
survey 2010-2012
8
hypertension korea
4

Similar Publications

A case of corneal opacity caused by atovaquone administration.

Am J Ophthalmol Case Rep

March 2025

Department of Ophthalmology and Visual Sciences, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, 852-8501, Japan.

Purpose: Atovaquone is an alternative drug that is used for the prevention and treatment of pneumonia when the first-line drug, sulfamethoxazole-trimethoprim (ST combination), cannot be used due to side effects. However, atovaquone is known to cause ocular side effects including oculomucocutaneous syndrome and vortex keratopathy. In this report, we describe a patient who developed bilateral white granular diffuse corneal opacity that extended from the corneal sub-epithelium to the stroma after continuous oral atovaquone administration for 14 months.

View Article and Find Full Text PDF

A 50-year-old female presented with a 10-day history of progressive swelling and pain in the left lower extremity, ultimately diagnosed with deep vein thrombosis (DVT) and May-Thurner Syndrome (MTS). Initial ultrasound indicated thrombosis involving the left external iliac, femoral, and popliteal veins, among others. Blood tests revealed normocytic anemia, but thrombophilia screening and other blood markers were normal.

View Article and Find Full Text PDF

Background And Objective: Iron deficiency anemia (IDA) is a prominent cause of anemia adversely affecting the physical, mental, and social well-being of an individual. It is a major health concern and has impacted more than two billion people worldwide. It is necessary to implement programs to increase compliance rates for iron and folic acid (IFA) supplementation and educate individuals about anemia.

View Article and Find Full Text PDF

Heyde's syndrome is a clinical entity that combines aortic stenosis, gastrointestinal angiodysplasia, and an acquired von Willebrand factor disorder. This syndrome is characterized by the association between aortic stenosis and recurrent gastrointestinal bleeding episodes, typically linked to angiodysplasias. Effective treatment requires addressing the underlying condition, specifically aortic stenosis, which leads to the structural destruction of coagulation proteins, resulting in the acquired von Willebrand factor disorder and perpetuating the bleeding.

View Article and Find Full Text PDF

Unveiling unexpected adverse events: post-marketing safety surveillance of gilteritinib and midostaurin from the FDA Adverse Event Reporting database.

Ther Adv Drug Saf

January 2025

Department of Pharmacy, Daping Hospital, Army Medical University, No. 10 Changjiang Branch Road, Yuzhong District, Chongqing 400042, China.

Background: Gilteritinib and midostaurin are FLT3 inhibitors that have made significant progress in the treatment of acute myeloid leukemia. However, their real-world safety profile in a large sample population is incomplete.

Objectives: We aimed to provide a pharmacovigilance study of the adverse events (AEs) associated with gilteritinib and midostaurin through the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!